Getting Genomic Medicines Ready For Prime Time

By Laura Chadwick, Senior Marketing Writer, Cytiva

Discovering a promising new treatment is no small feat, but historically, the journey from early-stage success to making a positive impact on patients' lives has been lengthy. Due to the boost in research and development spurred by the pandemic, this journey is now being traversed faster and more efficiently by a greater number of molecules than ever before.

In the current landscape, characterized by a bustling nucleic acid space, there is a notable increase in both the volume of development and the pace of progress. To efficiently navigate this busy environment, adjustments in our approach to bringing these life-saving therapies to the clinic are necessary.

The reliable production of lipid nanoparticles (LNPs) plays a crucial role in transitioning the promising nucleic acid clinical pipeline into commercial production. Explore the benefits of building a manufacturing process early, the importance of reliable nanoparticle production in gene therapy, and how research into LNPs in nucleic acid therapeutics will contribute to the development of future drugs.